TwoOncDocs

601 posts

TwoOncDocs banner
TwoOncDocs

TwoOncDocs

@TwoOncDocs

🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi

Katılım Haziran 2022
1.8K Takip Edilen4.6K Takipçiler
TwoOncDocs
TwoOncDocs@TwoOncDocs·
Burnout is extremely prevalent in medicine & specifically in oncology - in this week’s episode we discuss Wellness in Oncology tips w/ @doclauravater & the SMILE Scale - a wellness behavioral tool designed to measure and encourage healthy habits ❤️‍🩹 podcasts.apple.com/us/podcast/two…
English
1
1
11
748
TwoOncDocs retweetledi
Karine Tawagi MD
Karine Tawagi MD@DrKarineTawagi·
A few months after ASCO GU, EVP is now FDA approved for cisplatin-eligible MIBC! 🎉 Now many trials looking at bladder preservation in pts w/ cCR inc: 🌟 HCRN GU22-598 ph2 @hoosiercancer 🌟 EV-PRIME @koshkin85 EVP+RT 🌟 CONSOLIDATE @OAlhalabiMD EVP+ RT 🌟 Astellas 7465 ph2
Karine Tawagi MD tweet media
Karine Tawagi MD@DrKarineTawagi

Groundbreaking KN-B15 for EVP in cis-eligible MIBC 👤 most T3/T4a, 90% pure urothelial 🎖️ EFS HR 0.53, OS HR 0.65, pCR 55.8% vs 32.5% ⚠️¾ grade 3 TEAE, 25% stopped NA EVP & 28.6% adj EVP d/t TEAE ‼️36% neuropathy, 63% skin, 23% 👁️ ❓how many got IO in control arm

English
0
7
28
3.8K
TwoOncDocs
TwoOncDocs@TwoOncDocs·
Welcome to all starting fellowship today!🎉 Remember it’s normal to feel overwhelmed (juggling call, studying for ABIM, sheer amount of new info to know), we are all a work in progress, it’s ok to ask for help Next week’s episode w/ @doclauravater will cover wellness tips🧡
TwoOncDocs tweet media
English
1
3
20
846
TwoOncDocs retweetledi
Paul H, PharmD, RPH
Paul H, PharmD, RPH@phsiao4·
Nice episode @TwoOncDocs I even encouraged my MD daughter( just started her OBGyn residency) to set up a goal for getting to know at least one Inpatient Pharmacist next few weeks. Definitely the best resource (drug related issues) podcasts.apple.com/us/podcast/two…
Paul H, PharmD, RPH tweet media
Paul H, PharmD, RPH@phsiao4

FaceTimed my MD daughter earlier. I suggested her to get to know at least one inpatient pharmacist on first name basis and be respectful to own hospital Formulary system. Learn drug cost if possible and be cost conscious. Residency starts Monday officially Good Luck!

English
0
1
5
733
TwoOncDocs
TwoOncDocs@TwoOncDocs·
Our newest episode out today with @doclauravater on the transition from fellow to attending & mistakes she made as a new attending physician (so you don’t have to) It really hit home for a lot of us, with tips on managing each of these 🫶🏼 podcasts.apple.com/us/podcast/two…
TwoOncDocs tweet media
English
2
10
19
3.8K
TwoOncDocs
TwoOncDocs@TwoOncDocs·
This week, we released an update on the #SARC041 trial from #ASCO26 plenary 🤩 ➡️ ph3 trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS) Next week, we have an extremely special guest & friend for a new 2 part series!! @doclauravater
TwoOncDocs@TwoOncDocs

🤩SARCOMA AT PLENARY!🎗️ 🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS 📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement 🎯 ORR: 9.3% vs 0% ⏳ OS trend favors abemaciclib (HR 0.55) 🔄 Crossover activity confirmed (mPFS 3.4 mo) #ASCO26

English
2
2
5
1.1K
TwoOncDocs retweetledi
Karine Tawagi MD
Karine Tawagi MD@DrKarineTawagi·
Join us 6/23 for a webinar with heme/onc PDs on what makes a successful heme/onc candidate & eventually fellow 💫
English
0
3
7
739
TwoOncDocs retweetledi
Antonio Ocejo
Antonio Ocejo@ja_ocejo·
📣 Oncology fellows: Applications are open for the 2026–2027 FDA/ASCO Fellows’ Day Workshop! Great way to learn from FDA oncology leaders about trial design, regulatory science, and the drug/device approval process through case-based discussions and Q&A. 📌Open to oncology fellows with at least one year of completed training. 🗓️ In-person + virtual options available, with up to $500 reimbursement for selected in-person participants. Apply by June 26: asco.smapply.org @ASCOTECAG @HemOncFellows @IMG_Oncologists
Antonio Ocejo tweet media
English
1
13
42
3.7K
Shreyas Kalantri, MD
Shreyas Kalantri, MD@KalantriShreyas·
Excited to share that I’ve been selected for the 2026 AACR/ASCO Methods in Clinical Cancer Research Workshop in Vail. Looking forward to developing my trial concept, learning from an incredible faculty group, and connecting with colleagues passionate about clinical trial design. Grateful for the opportunity and support from mentors who helped shape the application. #MedTwitter #OncTwitter #gusm
Shreyas Kalantri, MD tweet media
English
10
2
59
3.3K
TwoOncDocs
TwoOncDocs@TwoOncDocs·
That’s a wrap for #ASCO26 💕 We are excited to dive in to our key takeaways in next week’s episode including some of the plenary sessions (#RASolute ‼️#SARC1, #PROTREUS) & more 📅 & save the date for our #ASH26 free heme board review session for trainees Dec 11🩸 @OncBrothers
TwoOncDocs tweet media
English
4
7
40
2.4K
TwoOncDocs retweetledi
Allison Fitzgerald, MD, PhD
Allison Fitzgerald, MD, PhD@allisonoconn·
With all the excitement around daraxonrasib, I needed to refresh my RAS inhibitor knowledge, so here we go:
English
11
156
729
88.1K
TwoOncDocs retweetledi
Mark Lewis, MD, FASCO
Mark Lewis, MD, FASCO@marklewismd·
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26
English
92
1.3K
6.5K
1.2M
TwoOncDocs retweetledi
Yüksel Ürün
Yüksel Ürün@DrYukselUrun·
This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists
English
24
276
1.4K
196.2K
TwoOncDocs
TwoOncDocs@TwoOncDocs·
Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹 #RASolute today presented at #ASCO26: Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ +w/o RAS (mOS 13.2 mo vs. 6.6 mo) A HUGE advance in one of the most lethal cancers 💜
Chicago, IL 🇺🇸 English
1
16
47
1.7K
TwoOncDocs
TwoOncDocs@TwoOncDocs·
🤩SARCOMA AT PLENARY!🎗️ 🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS 📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement 🎯 ORR: 9.3% vs 0% ⏳ OS trend favors abemaciclib (HR 0.55) 🔄 Crossover activity confirmed (mPFS 3.4 mo) #ASCO26
TwoOncDocs tweet mediaTwoOncDocs tweet media
English
0
11
30
5.9K
TwoOncDocs
TwoOncDocs@TwoOncDocs·
🚨 first up #PROTEUS Phase 3 Adding peri-op apalutamide to ADT significantly improves outcomes for high-risk localized prostate cancer undergoing surgery: 🔹 pCR/MRD: 8.9% vs 1.0% (10x OR!) 🔹 5-y MFS: 78.2% vs 73.5% (HR 0.80) ⚠️ 8% more gr3/4 tx AEs #ProstateCancer #ASCO26
TwoOncDocs tweet mediaTwoOncDocs tweet mediaTwoOncDocs tweet mediaTwoOncDocs tweet media
Chicago, IL 🇺🇸 English
0
7
20
804

Keşfet

@doclauravater @hoosiercancer @koshkin85 @OAlhalabiMD @ASCO @KArnaoutakis @DrKarineTawagi @ASridharMD